Respiratory Distress Syndrome (RDS) in premature infants

Pulmonary Surfactants

1. CUROSURF is administered directly to the lung, where biophysical effects occur at the alveolar surface.
2. No human pharmacokinetic studies have been performed to characterize the absorption, biotransformation, or elimination of CUROSURF.

For those who have allergic reactions to the main ingredient or any excipients.

This drug is not indicated for use in adults.

This drug is not indicated for use in adults.

Common adverse reactions associated with the administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation.

1. Initial recommended dose is 2.5 mL/kg (200mg/kg) birth weight
2. Up to two repeat doses of 1.25 mL/kg birth weight may be administered at approximately 12-hour intervals
3. Maximum total dose (initial plus repeat doses) is 5 mL/kg
4. Administration :
(1). For the first dose: 1.25 mL/kg (birth weight) per aliquot
(2). For each repeated dose: 0.625 mL/kg (birth weight) per aliquot

Preparation of the CUROSURF Suspension:

1. Remove the vial of CUROSURF suspension from a refrigerator at +2°C to +8°C and slowly warm the vial to room temperature before use.
2. Gently turn the vial upside-down, in order to obtain a uniform suspension. DO NOT SHAKE.

Please see the dosage and administration instructions for details.

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling.

1. Unopened, unused vials of CUROSURF suspension that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use.
2. Do not warm to room temperature and return to refrigerated storage more than once.
3. Protect from light.